Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.

Cellular and molecular gastroenterology and hepatology - 1 Jan 2021

Xia Shunjie, Ji Lin, Tao Liye, Pan Yu, Lin Zhongjie, Wan Zhe, Pan Haoqi, Zhao Jie, Cai Liuxin, Xu Junjie, Cai Xiujun

Abstract excerpt

BACKGROUND & AIMS: Identifying novel and actionable targets in hepatocellular carcinoma (HCC) remains an unmet medical need. TAK1 was originally identified as a transforming growth factor-β-activated kinase and was further proved to phosphorylate and activate numerous downstream targets and promote cancer progression. However, the role of TAK1 in developed HCC progression and targeted therapy resistance is poorly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Hepatocellular
Share to F-Box Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hep G2 Cells

Share to MAP Kinase Kinase Kinases

Share to Proteolysis

Share to Sorafenib

Share to Ubiquitination

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 33962073
DOI: 10.1016/j.jcmgh.2021.04.016
PMCID: PMC8350196

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.PMID 33962073Read ↗

Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinomaSemantic proximity Read ↗

Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future DirectionsSemantic proximity Read ↗

Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinomaSemantic proximity Read ↗

SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinomaSemantic proximity Read ↗

Comprehensive Network Analysis of the Molecular Mechanisms Associated with Sorafenib Resistance in Hepatocellular CarcinomaSemantic proximity Read ↗

Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma CellsSemantic proximity Read ↗

Epigenetic regulation of DNA repair gene program by Hippo/YAP1-TET1 axis mediates sorafenib resistance in HCCSemantic proximity Read ↗

Molecular mechanisms of sorafenib action in liver cancer cellsSemantic proximity Read ↗

Pharmacological inhibition of deubiquitinase UCH-L1 by LDN57444 sensitises hepatocellular carcinoma to sorafenib by reverting drug-induced adaptive responsesSemantic proximity Read ↗

Expression and Function Analysis of Mitotic Checkpoint Genes Identifies TTK as a Potential Therapeutic Target for Human Hepatocellular CarcinomaSemantic proximity Read ↗

HTR1D regulates the PI3K/Akt signaling pathway to impact hepatocellular carcinoma development and resistance to sorafenibSemantic proximity Read ↗

Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.